Substance / Medication

Thyrotropin alfa

Overview

Active Ingredient
thyrotropin alfa
RxNorm CUI
4952
Labeler: Genzyme CorporationUpdated: 2023-02-24T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

If THYROGEN is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen. Refer to the radioiodine prescribing information for a list of contraindications for radioiodine.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick Ujjal, Harmer Clive, Yap Beng et al. · N Engl J Med · 2012
PMID: 22551128Observational
Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).
Gonzalez Marta E, Muttikkal Thomas Jose Eluvathingal, Rehm Patrice K · J Radiol Case Rep · 2015
PMID: 26622936Case ReportFull text (PMC)
Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation.
Juweid Malik, O'Dorisio Thomas, Milhem Mohammed · N Engl J Med · 2008
PMID: 18799567Case Report
Fourier Transform Near-Infrared Spectrometry Reveals Significant Inter-Lot Variability in Thyrotropin Alfa (Thyrogen) Quality.
Yoon Uiyeol, Tarianto Ayumi, Almeter Philip J et al. · Contact Context · 2025
PMID: 41306796OtherFull text (PMC)
Quality Variations in Thyrotropin Alfa.
Isaacs James T, Almeter Philip J, Henderson Bradley S et al. · Contact Context · 2023
PMID: 37396298OtherFull text (PMC)
Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
Simões-Pereira Joana, Ferreira Teresa C, Limbert Edward et al. · Thyroid · 2021
PMID: 34155923Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Thyrotropin alfa (substance)
SNOMED CT
412520006
UMLS CUI
C2587204
RxNorm CUI
4952
Labeler
Genzyme Corporation

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.